GnRH Agonists: Safety Review of Drug Class Used to Treat Prostate Cancer

Possible increased risk of diabetes and certain cardiovascular diseases.

Related Posts:

1. Benicar (olmesartan): Ongoing Safety Review
2. Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review
3. Proton Pump Inhibitors (PPI): Class Labeling Change
4. Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
5. Rare Diseases Pose Medico-legal Risk, From Medical And Dental Defence Union Of Scotland